Akums Drugs and Pharmaceuticals Limited — Others, 13-11-2024: Monitoring Agency Report

Akums Drugs and Pharmaceuticals Limited has issued a report from CRISIL Ratings concerning the utilization of proceeds from its Initial Public Offer (IPO) for the quarter ended September 30, 2024. The report confirms that there were no deviations in the use of proceeds compared to the initial disclosures in the offer document. The IPO raised ₹6,800 million, with net proceeds of ₹6,373.70 million after expenses. As of the report, ₹2,219.03 million remains unutilized, primarily held in fixed deposits and public offer accounts. This stable financial position bodes well for investor confidence, suggesting a positive outlook for future operations and growth strategies.